Obese plasma transfer accelerates cellular aging in the C57BL/6 mouse model Authors: Shabnam Shahabi Nejad, Hamid Zand, Samira Rastgoo, Leyli Zahra Bahreini Boroujeni, Mehdi Abedini Najafabadi, Saman Asadi, Reyhane Hamishe Bahar, Ghazaleh Shimi Published: 2025 ABSTRACT BackgroundObesity induces chronic inflammation and cellular senescence, contributing to metabolic and immune dysfunction. This study investigates the effects of plasma obtained from obese and non-obese C57BL/6 donor mice on senescence and inflammation markers in recipient mice.MethodsRecipient C57BL/6 mice received intraperitoneal injections of 150 μl of pooled plasma from either obese (PO group) or non-obese (PNO group) donors once weekly for four weeks. Body weight, epididymal adiposity index, and thymus index were recorded. Senescence-associated β-galactosidase (SA-β-gal) activity was assessed in epididymal white adipose tissue (eWAT) and peripheral blood mononuclear cells (PBMCs). Gene expression of p16, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) was quantified using quantitative real-time polymerase chain reaction (qRT-PCR). Plasma concentrations of IL-6 and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA).ResultsMice in the PO group showed significantly increased SA-β-gal activity in eWAT (P < 0.05) and PBMCs (P < 0.001) compared to the PNO group. In eWAT, p16 expression was significantly elevated (P = 0.019; log₁₀-fold change: 1.48). In PBMCs, IL-6 (P < 0.001; log₁₀-fold change: 0.90), p16 (P < 0.001; log₁₀-fold change: 1.41), and TNF-α (P < 0.001; log₁₀-fold change: 2.83) expressions were significantly upregulated in the PO group. No significant differences were observed in plasma cytokines, body weight, epididymal adiposity, or thymus index.ConclusionsThese results indicate that the pro-inflammatory and pro-senescence effects of obese plasma are not limited to the original donor but can actively transfer aging-related changes and immune dysfunctions to healthy recipient tissues, highlighting the need for further therapeutic exploration. Background Obesity is a complex nutritional disorder characterized by an imbalance between energy intake and expenditure and has become one of the most significant global public health challenges [1]. Substantial evidence indicates that obesity is closely associated with chronic low-grade inflammation, which contributes to various metabolic disturbances, including insulin resistance, diabetes, dyslipidemia, cardiovascular diseases, metabolic syndrome, and certain cancers [2]. Beyond these complications, obesity has been linked to molecular and cellular stress responses such as DNA damage, telomere shortening, and organelle dysfunction [3], which are major contributors to cellular senescence and age-related functional decline [4]. Cellular senescence is defined by an irreversible cell-cycle arrest accompanied by the acquisition of a specific secretory phenotype known as the senescence-associated secretory phenotype (SASP), characterized by the release of pro-inflammatory cytokines, growth factors, and proteases [5]. While SASP factors play physiological roles in recruiting immune cells to clear senescent cells, their chronic secretion can lead to pathological conditions, including exacerbated metabolic diseases [5, 6]. Senescent cells accumulate in adipose tissue during obesity, promoting local and systemic inflammation via SASP factors, thereby impairing tissue function and contributing to metabolic decline [7]. Moreover, senescent immune cells may accumulate, further compromising the immune system’s ability to clear damaged cells and exacerbating immunosenescence, a process linked to both aging and obesity [6]. This immunosenescence involves both innate and adaptive immune responses, including impaired T cell proliferation, increased pro-inflammatory cytokine production, and persistent low-grade inflammation, which collectively deteriorate immune defense and promote chronic diseases [8, 9]. Almost all known inducers of senescence are abnormally elevated in obesity and can promote this process across multiple organs. Notably, the clearance of senescent cells using senotherapeutic agents has been shown to improve metabolic health and alleviate obesity-related comorbidities [7, 10]. Senotherapeutics include compounds that either eliminate senescent cells (senolytics) or suppress SASP (senomorphics) [11]. Emerging therapies targeting senescent cells in obesity are currently under clinical investigation and may lead to the development of treatments for obesity-associated metabolic disorders and age-related diseases. On the other hand, findings from heterochronic parabiosis models, where the circulatory systems of young and old animals are connected, support the role of circulating factors in regulating aging [12]. Promising studies have explored the anti-aging effects of blood from young individuals, demonstrating that, in various biological models, the administration of blood-derived factors from young animals to aged counterparts has been shown to extend lifespan, suggesting that blood-based therapies may offer novel interventions for age-related diseases [13]. Given that obesity promotes systemic inflammation and senescence-associated factors in circulation, it is hypothesized that blood from obese individuals may transfer senescence-associated dysfunctions, potentially leading to functional alterations in recipients. However, direct evidence of this plasma-mediated transfer of senescence remains limited. The present study aims to investigate the effects of plasma from obese versus normal-weight C57BL/6 donor mice on markers of senescence and inflammation in adipose tissue and peripheral blood mononuclear cells (PBMCs) of recipient mice. Findings may provide novel insights into obesity-induced systemic senescence and inform future senotherapeutic interventions to mitigate metabolic and immune aging associated with obesity. Materials and methods All animal experiments were performed in accordance with the guidelines established by the National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, pertaining to the ethical care and utilization of animals (code of ethics committee: IR.SBMU.NNFTRI.REC.1402.067). Plasma donor mice and blood collection Thirty male C57BL/6 mice, aged six to eight weeks (mean weight 26.44 ± 2.00 g), were obtained from the Royan Institute (Tehran, Iran). The mice were individually housed in clean cages under standard conditions (temperature: 22 ± 2 °C, humidity: 50 ± 10%, a 12-h light/dark cycle). To help the animals adjust, they were given ad libitum access to a standard rodent diet and tap water for one week. After this acclimatization period, the mice were randomly divided into two groups: one group was fed a high-fat diet (HFD group; n = 15) and the other group received a normal diet (ND group; n = 15). The HFD had an energy content of 5.2 kcal/g, consisting of 60% fat, 20% carbohydrates, and 20% protein, while the ND provided 3.3 kcal/g, with 10% fat, 60% carbohydrates, and 30% protein. Table 1 displays the composition of both diets, which were created by the Royan Institute. The body weight measurements were conducted on a weekly basis between 09:00 and 10:00 a.m., and when the weight of mice in the HFD group was significantly higher than the ND group after 23 weeks (37.60 ± 5.04 g versus 31.10 ± 2.60 g; P < 0.001), about 21% more than the ND group, an obesity model was established (Fig. 1). Following the induction of obesity in the animals, anesthesia was administered using 75 mg/kg of ketamine, 10 mg/kg of xylazine, and 5 mg/kg of midazolam. Subsequently, the abdominal circumference was measured and recorded. After euthanasia, white adipose tissue from the epididymal region (eWAT) was removed, rinsed with PBS, and weighed. The epididymal adiposity index, which is used to evaluate obesity, was determined using this formula: [weight of epididymal fat pad (g)/body weight (g)] × 100 [14]. Additionally, blood samples were obtained through cardiac puncture and were collected in a K2 EDTA vacutainer (Hebei Xinle Medical, Shijiazhuang, China).Table 1Composition of normal and high fat dietNutritive ingredientsNDHFDCasein (mg%)1524Soybean meal (g%)2310Corn32.50Corn starch (g%)1220Sucrose (g%)108Soybean oil (g%)2.52Lard (g%)031Mineral and vitamin premix (g%)55Total100100g%Kcal%g%Kcal%Protein23302420Carbohydrate50.3602620Fat5.1103560Total3.3(kcal/g)1005.2(kcal/g)100ND Normal diet, HFD High fat dietFig. 1Outline of the study protocol. HFD: High-fat diet; ND: Normal diet; PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice Table 1Composition of normal and high fat dietNutritive ingredientsNDHFDCasein (mg%)1524Soybean meal (g%)2310Corn32.50Corn starch (g%)1220Sucrose (g%)108Soybean oil (g%)2.52Lard (g%)031Mineral and vitamin premix (g%)55Total100100g%Kcal%g%Kcal%Protein23302420Carbohydrate50.3602620Fat5.1103560Total3.3(kcal/g)1005.2(kcal/g)100ND Normal diet, HFD High fat diet Composition of normal and high fat diet ND Normal diet, HFD High fat diet Outline of the study protocol. HFD: High-fat diet; ND: Normal diet; PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice Plasma pooling and dialysis Blood samples placed in tubes containing K2 EDTA, as an anticoagulant, were subjected to centrifugation at 3000 RPM for 10 min at 4 °C. Following this process, the supernatant, which represents the plasma fraction, was collected. Plasma samples from mice subjected to an HFD and those on an ND were pooled and subsequently dialyzed using dialysis membrane bags that have been sealed at both ends (SERVAPOR® Dialysis Tubing, 3.5 kDa molecular weight cut-off, Diameter 35 mm, Germany) in 1X phosphate-buffered saline (PBS) to remove EDTA. The samples were washed four times for two hours in PBS, followed by an additional overnight wash at 4 °C. Following dialysis, the samples were stored at − 80 °C. Plasma receiver mice A total of 10 male C57BL/6 mice (6—8 weeks old, mean weight: 18.76 ± 1.70 g) were purchased from the Royan Institute (Tehran, Iran). The mice were housed individually in sanitized cages under controlled environmental conditions, specifically at a temperature of 22 ± 2 °C, humidity levels of 50 ± 10%, and a 12-h light/dark cycle. To facilitate acclimatization, the mice were provided with ad libitum access to a standard rodent diet and tap water for one week. Following this acclimatization phase, the mice were randomly assigned to two weight-matched feeding groups: one group receiving the pool of plasma from obese donor mice (PO group; n = 5), while the other group was treated with the pool of plasma from non-obese donor mice (PNO group; n = 5). The two groups received an intraperitoneal administration of 150 μl of pooled plasma once a week for four weeks (Fig. 1). No animals died at any point during the experiment. The body weight was recorded weekly between 09:00 and 10:00 a.m., and at the end of the experimental period mice were anesthetized by using 75 mg/kg of ketamine, 10 mg/kg of xylazine, and 5 mg/kg of midazolam before being sacrificed. Subsequently, blood samples were obtained through cardiac puncture, and plasma was isolated by centrifugation at 3000 RPM for 15 min. The resulting plasma was stored at − 80 °C until further analysis. White adipose tissue depots from the eWAT were rapidly removed, washed with PBS, weighed for the analysis of epididymal adiposity index, and then rapidly frozen in liquid nitrogen. Additionally, fresh thymus tissues were collected and weighed. The thymus index was calculated using the following formula: [thymus weight (mg)/body weight (g)] × 10 [15]. PBMCs isolation For the isolation of PBMCs, a volume of 600–1,000 μL of blood was diluted with PBS to achieve a final volume of 4 mL. Subsequently, 2 mL of Ficoll (Lymphodex, Innotrain, Germany) was carefully pipetted into the bottom of a 15 mL conical centrifuge tube. The diluted blood was then gently layered on top of the Ficoll gradient and subjected to centrifugation at 1140 RPM for 15 min, with the brake off. Following centrifugation, the PBMC layer, also known as the buffy coat, was meticulously collected. Senescence-associated beta-galactosidase (SA-β-Gal) activity in PBMCs and eWAT To assess SA-β-gal activity, an optimized cytochemical assay was employed for PBMCs and eWAT. For the PBMCs, cells were fixed using a solution of 37% formaldehyde and 50% glutaraldehyde in PBS. Subsequently, the cells were incubated overnight at 37 °C in a freshly prepared staining solution at pH 6.0, which contained 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2·6H2O, 150 mM NaCl, 40 mM citric acid/phosphate buffer, and 1 mg/mL of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal, BioBasic, Canada). Following incubation, the cells were washed with PBS, examined at × 40 magnification, and photographed using a Ceti microscope. The proportion of green pixels relative to the total pixel count was evaluated utilizing ImageJ software (Bethesda, MD, USA), in order to quantify β-galactosidase activity. For the eWAT, a total of 500 μL of the staining solution at pH 6.0, comprising 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2·6H2O, 150 mM NaCl, 40 mM citric acid/phosphate buffer, and 1 mg/mL of X-Gal (BioBasic, Canada), was applied and incubated overnight at 37 °C. After the incubation period, tissues were washed with PBS, and the reaction was subsequently terminated by the application of a fixation buffer composed of 37% formaldehyde and 50% glutaraldehyde in PBS. Subsequently, the tissues were analyzed, and photographic records were obtained. The quantification of β-galactosidase activity was conducted using ImageJ software, which involved evaluating the ratio of green pixels to the overall pixel count (Bethesda, MD, USA). Cytokine assay The plasma concentrations of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were quantified using enzyme-linked immunosorbent assay (ELISA) kits (Karmania Pars Gene Company, Iran), following the manufacturer's instructions. The kits utilize a quantitative sandwich enzyme immunoassay method. Each test was conducted in duplicate and analyzed at 450 nm. The sensitivity levels of the ELISA kits were as follows: IL-6 at 2 pg/mL and TNF-α at 8 pg/mL, with the intra-assay CV < 3% and inter-assay CV < 8% for IL-6 and the intra-assay CV < 5% and inter-assay CV < 10% for TNF-α. Gene expression measurements by quantitative reverse transcription–polymerase chain reaction (qRT-PCR) Total RNA was extracted from the eWAT and PBMCs of mice utilizing NorexPlus RNA extraction kits (NAT Biotech, Iran), in accordance with the manufacturer's guidelines. For cDNA synthesis, 300 ng of total RNA from adipose tissue and 100 ng from PBMCs were employed, using the NATScript cDNA synthesis kit (NAT Biotech, Iran) as per the manufacturer's instructions. The PCR for IL-6, p-16, TNF-α, and 18S rRNA (as an internal control) was conducted in duplicate. The reaction mixture comprised 10 μL of the SYBR Green Amplicon master mix (Ampliqon, Denmark), 7 μL of double-distilled water, 0.5 μL of forward primer (10 pmol/µL), 0.5 μL of reverse primer (10 pmol/µL), and 2 μL of cDNA, resulting in a final volume of 20 μL. Following an initial denaturation step lasting 15 min at 95 °C, 40 cycles of amplification were performed. Every two-step cycle consisted of a denaturation step lasting 25 s at 95 °C, followed by an annealing step of 25 s at 58 °C for eWAT and 56 °C for PBMCs. This procedure was conducted using the StepOnePlus real-time PCR system (Applied Biosciences, Paisley, UK). The gene expression levels were quantified as fold changes, calculated using the formula 2 −ΔΔCt. The primers used are shown in Table 2.Table 2The primers used for real-time PCR analysisGene nameSequence (5’ → 3’)Product length (bp)p-16F: CAG AGC TAA ATC CGG CCT CAR: TCC CTC CCG TGA TTG CAA A123IL-6F: AGT CAA TTC CAG AAA CCG CTAR: ATC AGT CCC AAG AAG GCA AC73TNF-αF: GGT GCC TAT GTC TCA GCC TCT TR: GCC ATA GAA CTG ATG AGA GGG AG13918S rRNAF: CGG GGA GGT AGT GAC GAAR: ACC AGA CTT GCC CTC CAA110Bp Base Pair Table 2The primers used for real-time PCR analysisGene nameSequence (5’ → 3’)Product length (bp)p-16F: CAG AGC TAA ATC CGG CCT CAR: TCC CTC CCG TGA TTG CAA A123IL-6F: AGT CAA TTC CAG AAA CCG CTAR: ATC AGT CCC AAG AAG GCA AC73TNF-αF: GGT GCC TAT GTC TCA GCC TCT TR: GCC ATA GAA CTG ATG AGA GGG AG13918S rRNAF: CGG GGA GGT AGT GAC GAAR: ACC AGA CTT GCC CTC CAA110Bp Base Pair The primers used for real-time PCR analysis F: CAG AGC TAA ATC CGG CCT CA R: TCC CTC CCG TGA TTG CAA A F: AGT CAA TTC CAG AAA CCG CTA R: ATC AGT CCC AAG AAG GCA AC F: GGT GCC TAT GTC TCA GCC TCT T R: GCC ATA GAA CTG ATG AGA GGG AG F: CGG GGA GGT AGT GAC GAA R: ACC AGA CTT GCC CTC CAA Bp Base Pair Statistical analyses Statistical analyses were conducted utilizing SPSS software (version 27). The Shapiro–Wilk test was employed to assess whether the numerical variables follow a normal distribution. The difference between the two groups was analyzed using an independent samples t-test for variables that follow a normal distribution, and the Mann–Whitney U test for variables that do not follow a normal distribution. A p-value of less than 0.05 indicated a statistically significant difference. Results Body weights and anthropometric results of the plasma donor mice (HFD and ND groups) At the beginning of the study, there were no statistically significant differences in body weight (g) between HFD and ND groups (25.72 ± 1.88 g versus 25.17 ± 1.28 g; P = 0.273). A significant difference in body weight between these two groups was first observed at week three (27.44 ± 1.86 g versus 26.24 ± 1.40 g; P < 0.05), representing an approximate 4.6% increase in the HFD group compared to the ND group. Although this initial difference was statistically significant and persisted throughout the dietary intervention period, it did not meet the commonly accepted threshold for obesity in mouse models, which is typically defined as a 20–30% increase in body weight relative to the control group [16]. Following a 23-week implementation of the experimental protocol for the plasma donor mice, those subjected to an HFD exhibited a significant increase in body weight, with an elevation of 21% relative to their counterparts that were maintained on an ND (37.60 ± 5.04 g versus 31.10 ± 2.60 g; P < 0.001) (Fig. 2A). The mice in the HFD group exhibited an epididymal adiposity index of 4.53 ± 0.70, which was significantly higher than that of the ND group (2.53 ± 0.67) (P < 0.001) (Fig. 2B). Furthermore, at the end of the experimental period, abdominal circumference (cm) was found to be significantly higher (P < 0.001) in animals subjected to an HFD (9.61 ± 0.90) in comparison to those on an ND (8.59 ± 0.62). Figure 3 presents a comparison of body weight, waist circumference, and epididymal adiposity index between the HFD and ND groups following a 23-week dietary intervention.Fig. 2Effects of normal and high-fat diets on the appearance of the mice and eWAT in C57BL/6 mice. A Representative picture of mice following a 23-week regimen of either an ND or an HFD. B Representative images of eWAT from ND and HFD mice after 23 weeks of dietary intervention. Yellow arrows indicate eWAT. HFD: High-fat diet; ND: Normal diet; eWAT: Epididymal white adipose tissueFig. 3Comparison of body weight, waist circumference, and epididymal adiposity index between HFD and ND groups after 23 weeks of dietary intervention. A Graph showing body weight changes over the 23-week duration of the experimental protocol. A statistically significant difference between groups was evident from week three onwards. B Waist circumference and C epididymal adiposity index results at the end of the dietary intervention. The weight (37.60 ± 5.04 versus 31.10 ± 2.60 gr; P < 0.001), waist circumference (9.61 ± 0.90 versus 8.59 ± 0.62 cm; P < 0.001), and epididymal adiposity index (4.53 ± 0.70 versus 2.53 ± 0.67; P < 0.001) of mice in the HFD group was significantly higher than the ND group at the end of the dietary intervention. Data are presented as mean ± SD. Statistical significance is indicated as follows: * P < 0.05, $ P < 0.01, and # P < 0.001. HFD: High-fat diet; ND: Normal diet Effects of normal and high-fat diets on the appearance of the mice and eWAT in C57BL/6 mice. A Representative picture of mice following a 23-week regimen of either an ND or an HFD. B Representative images of eWAT from ND and HFD mice after 23 weeks of dietary intervention. Yellow arrows indicate eWAT. HFD: High-fat diet; ND: Normal diet; eWAT: Epididymal white adipose tissue Comparison of body weight, waist circumference, and epididymal adiposity index between HFD and ND groups after 23 weeks of dietary intervention. A Graph showing body weight changes over the 23-week duration of the experimental protocol. A statistically significant difference between groups was evident from week three onwards. B Waist circumference and C epididymal adiposity index results at the end of the dietary intervention. The weight (37.60 ± 5.04 versus 31.10 ± 2.60 gr; P < 0.001), waist circumference (9.61 ± 0.90 versus 8.59 ± 0.62 cm; P < 0.001), and epididymal adiposity index (4.53 ± 0.70 versus 2.53 ± 0.67; P < 0.001) of mice in the HFD group was significantly higher than the ND group at the end of the dietary intervention. Data are presented as mean ± SD. Statistical significance is indicated as follows: * P < 0.05, $ P < 0.01, and # P < 0.001. HFD: High-fat diet; ND: Normal diet Body weights, anthropometrics, and thymus index results of the plasma receiver mice (PO and PNO groups) At the beginning of the study, the weight of the mice showed similar values for both the PO (21.46 ± 2.24) and PNO (22.32 ± 1.62) groups (P = 0.507). At the end of the study protocol, there were no statistically significant differences between obese and non-obese plasma treatments for plasma receiver mice in weight (24.98 ± 2.10 g versus 26.44 ± 2.44 g; P = 0.340), epididymal adiposity index (2.16 ± 0.28 versus 2.29 ± 0.51; P = 0.640), and thymus index (22.50 ± 8.81 versus 34.75 ± 14.08; P = 0.138) (Fig. 4).Fig. 4Body weight, epididymal adiposity index, and thymus index results of the experimental mice. A Graph showing body weight changes for the PO and PNO groups during the experimental protocol. B Epididymal adiposity index results at the end of the study. C Thymus index results: measurements of the thymus index conducted at the end of the study. There were no statistically significant differences between PO and PNO groups in weight (24.98 ± 2.10 versus 26.44 ± 2.44 gr; P = 0.340), epididymal adiposity index (2.16 ± 0.28 versus 2.29 ± 0.51; P = 0.640), and thymus index (22.50 ± 8.81 versus 34.75 ± 14.08; P = 0.138) at the end of the study. Data are presented as mean ± SD. PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice Body weight, epididymal adiposity index, and thymus index results of the experimental mice. A Graph showing body weight changes for the PO and PNO groups during the experimental protocol. B Epididymal adiposity index results at the end of the study. C Thymus index results: measurements of the thymus index conducted at the end of the study. There were no statistically significant differences between PO and PNO groups in weight (24.98 ± 2.10 versus 26.44 ± 2.44 gr; P = 0.340), epididymal adiposity index (2.16 ± 0.28 versus 2.29 ± 0.51; P = 0.640), and thymus index (22.50 ± 8.81 versus 34.75 ± 14.08; P = 0.138) at the end of the study. Data are presented as mean ± SD. PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice SA-β-gal activity results in eWAT and PBMCs of the PO and PNO groups After the four-week intervention, significant differences were observed in cellular senescence between PO and PNO recipient mice. The quantification of SA-β-gal staining (%) in eWAT revealed significantly higher levels in the PO group compared to the PNO group (98.56 [14.94] versus 0.76 [66.02]; P < 0.05) (Fig. 5A). In parallel, the analysis of PBMCs demonstrated that the PO group exhibited a significant increase in SA-β-gal activity (%) relative to the PNO group (7.98 ± 1.12 versus 3.96 ± 1.09; P < 0.001) (Fig. 5B).Fig. 5Comparison of SA-β-gal activity (%) in eWAT and PBMCs between PO and PNO groups, at the end of the study. A. SA-β-gal activity (%) in eWAT was significantly higher in the PO group (n = 5) compared to the PNO group (n = 5) (98.56 [14.94] versus 0.76 [66.02]; P < 0.05). B In PBMCs, the PO group (n = 5) also showed a significant increase in SA-β-gal activity (%) compared to the PNO group (n = 5) (7.98 ± 1.12, 7.98 [2.20] versus 3.96 ± 1.09, 3.96 [2.15]; P < 0.001). C Representative images of eWAT stained with X-gal (3 samples selected from 5 per group), showing increased blue-green coloration indicative of SA-β-gal positive cells in the PO group compared to the PNO group. D The color threshold analysis of PBMCs using ImageJ, where white areas represent SA-β-gal positive cells. The PO group exhibited a higher proportion of senescent PBMCs than the PNO group. Data are presented as mean ± SD and median [interquartile range]. Statistical significance is indicated as follows: * P < 0.05 and # P < 0.001. PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice; SA-β-gal: Senescence-associated beta-galactosidase; eWAT: Epididymal white adipose tissue; PBMCs: Peripheral blood mononuclear cells Comparison of SA-β-gal activity (%) in eWAT and PBMCs between PO and PNO groups, at the end of the study. A. SA-β-gal activity (%) in eWAT was significantly higher in the PO group (n = 5) compared to the PNO group (n = 5) (98.56 [14.94] versus 0.76 [66.02]; P < 0.05). B In PBMCs, the PO group (n = 5) also showed a significant increase in SA-β-gal activity (%) compared to the PNO group (n = 5) (7.98 ± 1.12, 7.98 [2.20] versus 3.96 ± 1.09, 3.96 [2.15]; P < 0.001). C Representative images of eWAT stained with X-gal (3 samples selected from 5 per group), showing increased blue-green coloration indicative of SA-β-gal positive cells in the PO group compared to the PNO group. D The color threshold analysis of PBMCs using ImageJ, where white areas represent SA-β-gal positive cells. The PO group exhibited a higher proportion of senescent PBMCs than the PNO group. Data are presented as mean ± SD and median [interquartile range]. Statistical significance is indicated as follows: * P < 0.05 and # P < 0.001. PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice; SA-β-gal: Senescence-associated beta-galactosidase; eWAT: Epididymal white adipose tissue; PBMCs: Peripheral blood mononuclear cells Representative X-gal-stained images of eWAT further supported these findings, with adipose samples from the PO group displaying intense blue-green coloration indicative of elevated senescent cell content, whereas tissues from the PNO group appeared largely unstained (Fig. 5C). Similarly, color threshold analysis of PBMCs highlighted a greater proportion of SA-β-gal positive cells in the PO group compared to the PNO group, with these senescent cells appearing as distinct white-stained areas in the processed images (Fig. 5D). Plasma concentrations of pro-inflammatory cytokines in the PO and PNO groups At the end of the study, plasma concentrations of the pro-inflammatory cytokines TNF-α (pg/ml) and IL-6 (pg/ml) were quantified in recipient mice that had received plasma from obese or non-obese donors. The analysis revealed no statistically significant differences between the PO and PNO groups for TNF-α (7.66 [7.77] versus 6.76 [4.70]; P = 0.754) or IL-6 (5.90 [2.16] versus 4.17 [6.63]; P = 0.753) concentrations (Fig. 6).Fig. 6Plasma concentrations of pro-inflammatory cytokines in the experimental groups. A TNF-α concentration and B IL-6 concentration in PO and PNO groups at the end of the study. There were no statistically significant differences between PO and PNO groups in TNF-α (7.66 [7.77] versus 6.76 [4.70]; P = 0.754) and IL-6 (5.90 [2.16] versus 4.17 [6.63]; P = 0.753) levels. Data are presented as median [interquartile range]. PO: The group receiving the pool of plasma from obese donor mice; PNO: The group receiving the pool of plasma from non-obese donor mice; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha Plasma concentrations of pro-inflammatory cytokines in the experimental groups. A TNF-α concentration and B IL-6 concentration in PO and PNO groups at the end of the study. There were no statistically significant differences between PO and PNO groups in TNF-α (7.66 [7.77] versus 6.76 [4.70]; P = 0.754) and IL-6 (5.90 [2.16] versus 4.17 [6.63]; P = 0.753) levels. Data are presented as median [interquartile range]. PO: The group receiving the pool of plasma from obese donor mice; PNO: The group receiving the pool of plasma from non-obese donor mice; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha Gene expression analysis of IL-6, p16, and TNF-α in eWAT and PBMCs of the PO and PNO groups After analysis of real-time PCR raw data and analysis of expression log10-fold change, our results indicated that in eWAT, the level of p16 gene expression was significantly higher in the PO group compared to the PNO group (P = 0.019; log10-fold change: 1.48). Although expression levels of IL-6 (P = 0.438; log10-fold change: 0.94) and TNF-α (P = 0.344; log10-fold change: 0.38) were also higher in the PO group, these differences were not statistically significant (Fig. 7A).Fig. 7Comparison of ΔCT mean ± SD values of IL-6, p16, and TNF-α gene expressions between PO and PNO groups in eWAT and PBMCs. A Analysis of gene expression patterns in eWAT: this section presents an overview of gene expression profiles identified in eWAT at the study endpoint. B Analysis of gene expression levels in PBMCs: this section provides a comprehensive overview of the gene expression profiles detected in peripheral PBMCs at the end of the study. In adipose tissue, ΔCT mean values of p16 was significantly lower in the PO group compared to the PNO group (9.01 ± 1.42 versus 13.94 ± 2.74; log10-fold change: 1.48; P = 0.019), while no significant differences in ΔCT mean values were found in IL-6 (17.53 ± 6.44 versus 20.65 ± 5.62; log10-fold change: 0.94; P = 0.438) and TNF-α (12.15 ± 0.90 versus 13.40 ± 2.64; log10-fold change: 0.38; P = 0.344) between PO and PNO groups. In PBMCs, ΔCT mean values of all three genes were significantly lower in the PO group compared to the PNO group: IL-6 (19.07 ± 0.56 versus 22.05 ± 0.45; log10-fold change: 0.90; P < 0.001), p16 (16.95 ± 0.51 versus 21.62 ± 0.59; log10-fold change: 1.41; P < 0.001), and TNF-α (13.45 ± 0.36 versus 22.84 ± 0.70; log10-fold change: 2.83; P < 0.001). Gene expression was quantified using the 2^–ΔΔCT method and expressed as log₁₀-fold change. The higher ΔCT values indicate lower gene expression. Statistical significance is indicated as follows: * P < 0.05 and # P < 0.001. PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice; eWAT: Epididymal white adipose tissue; PBMCs: Peripheral blood mononuclear cells; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha Comparison of ΔCT mean ± SD values of IL-6, p16, and TNF-α gene expressions between PO and PNO groups in eWAT and PBMCs. A Analysis of gene expression patterns in eWAT: this section presents an overview of gene expression profiles identified in eWAT at the study endpoint. B Analysis of gene expression levels in PBMCs: this section provides a comprehensive overview of the gene expression profiles detected in peripheral PBMCs at the end of the study. In adipose tissue, ΔCT mean values of p16 was significantly lower in the PO group compared to the PNO group (9.01 ± 1.42 versus 13.94 ± 2.74; log10-fold change: 1.48; P = 0.019), while no significant differences in ΔCT mean values were found in IL-6 (17.53 ± 6.44 versus 20.65 ± 5.62; log10-fold change: 0.94; P = 0.438) and TNF-α (12.15 ± 0.90 versus 13.40 ± 2.64; log10-fold change: 0.38; P = 0.344) between PO and PNO groups. In PBMCs, ΔCT mean values of all three genes were significantly lower in the PO group compared to the PNO group: IL-6 (19.07 ± 0.56 versus 22.05 ± 0.45; log10-fold change: 0.90; P < 0.001), p16 (16.95 ± 0.51 versus 21.62 ± 0.59; log10-fold change: 1.41; P < 0.001), and TNF-α (13.45 ± 0.36 versus 22.84 ± 0.70; log10-fold change: 2.83; P < 0.001). Gene expression was quantified using the 2^–ΔΔCT method and expressed as log₁₀-fold change. The higher ΔCT values indicate lower gene expression. Statistical significance is indicated as follows: * P < 0.05 and # P < 0.001. PO group: The group receiving the pool of plasma from obese donor mice; PNO group: The group receiving the pool of plasma from non-obese donor mice; eWAT: Epididymal white adipose tissue; PBMCs: Peripheral blood mononuclear cells; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha In contrast, PBMCs from the PO group displayed significantly higher expression of IL-6 (P < 0.001; log10-fold change: 0.90), p16 (P < 0.001; log10-fold change: 1.41), and TNF-α (P < 0.001; log10-fold change: 2.83), compared to the PNO group (Fig. 7B). Discussion Obesity is a chronic inflammatory condition linked to metabolic problems and age-related changes, marked by the gradual accumulation of senescent cells, which are cells that have ceased to divide but are still metabolically active and release pro-inflammatory factors [17]. The association between obesity and an elevated burden of senescent cells indicates that plasma derived from obese individuals may convey pro-senescent signals to recipient tissues. Consequently, our research aimed to assess the phenotypic and molecular effects of plasma transfer in recipient mice. Focusing first on phenotypic parameters, in the present study, no statistically significant differences were identified in weight, epididymal adiposity, or thymus index between the groups receiving plasma from obese and non-obese donors. Turning to molecular effects, mice administered plasma from obese donors exhibited elevated markers indicative of cellular senescence. Notably, there was a significant increase in SA-β-gal activity observed in both PBMCs and eWAT. Furthermore, the expression of the p16 gene was markedly higher in the eWAT of the PO group in comparison to the PNO group. Although gene expression levels of IL-6 and TNF-α in eWAT were also elevated in the PO group, these differences did not reach statistical significance. Additionally, PBMCs from the group receiving obese plasma demonstrated significantly increased expression of pro-inflammatory and senescence-associated genes, specifically IL-6, TNF-α, and p16, in comparison to the non-obese plasma group. Despite these observed changes in cellular and gene expression, plasma concentrations of TNF-α and IL-6 did not show significant differences between the two groups. This experiment revealed no statistically significant differences in thymus index between PO and PNO groups; however, a lower index was observed in the PO group. This suggests that, within the study’s timeframe, plasma from obese sources did not substantially affect thymic size or function, but may still have subtle effects. The decrease in thymus index could signal impaired immune function, since the thymus is crucial for T cell development and its atrophy signals immunosenescence [5, 18]. These findings imply that obesity-related factors may contribute to immune decline, though further research is needed to confirm these effects. The increased activity of SA-β-gal and expression of the p16 gene in the eWAT of mice receiving plasma from obese donors indicated a rise in cellular senescence within adipose tissue [19]. Since p16 is a known inhibitor of the cell cycle and plays a key role in regulating senescence [20], its increased levels implied that exposure to plasma from obese animals led to a buildup of senescent cells, which could negatively affect the function of adipose tissue and overall metabolic health. Although there were also higher gene expression levels of IL-6 and TNF-α, these changes were not statistically significant, indicating that the pro-inflammatory response was only modest or in its early stages under the experimental conditions. This suggests that while obese plasma can set the stage for adipose tissue dysfunction by promoting senescence, a significant inflammatory response may require longer or more intense exposure. Our results are further supported by similar observations in cell culture models, where research indicated that culturing adipose-derived stem cells (ADSCs) in conditioned medium enriched with plasma from obese subjects induced senescence via the p38MAPK/NF-κB pathway. This process resulted in heightened secretion of IL-6 and IL-8, increased expression of p16 along with nuclear enlargement, and elevated SA-β-gal activity, highlighting the dysfunction and senescence of ADSCs caused by obesity [17]. The increased expression of genes linked to senescence and inflammation, such as IL-6, TNF-α, and p16, in PBMCs from mice treated with plasma from obese donors directly connected obesity to the acceleration of systemic immune aging, or immunosenescence. This process involved both inflammatory responses and cellular aging mechanisms. The rise in p16 supported the observed increase in SA-β-gal activity, while the elevated levels of IL-6 and TNF-α aligned with the development of a SASP, marked by intensified inflammatory signaling. Importantly, over 60% of PBMCs are T cells, with the rest comprising NK cells, monocytes, and B cells [21]. Given that T cells are especially prone to senescence due to their rapid proliferation, and other cell types may also contribute to immunological aging [2], these results collectively indicate heightened immunosenescence across the varied PBMC compartment. Moreover, although NK cells assist in removing senescent cells and controlling inflammation [22], immunosenescence in PBMCs can weaken NK cell activity and decrease their capacity to eliminate senescent cells, thereby exacerbating age-related diseases and speeding up immunosenescence. Supporting these observations, PBMCs from healthy donors, when cultured with plasma from obese individuals, exhibited increased cell death, decreased DNA damage response and mitochondrial function, elevated IL-1β and IL-8, reduced CD28 on CD8 + T cells, and altered macrophage activation, demonstrating a rapid induction of premature immune aging by obesity-related plasma [23]. Additionally, the data in this study demonstrated that SA-β-gal activity is elevated specifically in PBMCs, whereas the thymus remains unaffected, indicating that the observed senescence reflects a systemic cellular stress response that predominantly affects peripheral immune cells rather than thymic tissue. Interestingly, although PBMCs from the PO group exhibited higher levels of pro-inflammatory genes (IL-6, TNF-α), the plasma levels of TNF-α and IL-6 were not significantly different between the groups. This suggests that local cellular and tissue inflammation can occur without parallel increases in systemic markers, possibly due to compensatory mechanisms or the short plasma exposure period. This aligns with the idea that metaflammation, the persistent, mild immune activation seen in obesity, is often better detected at the cellular level than in systemic cytokine concentrations [24, 25]. The absence of notable changes in plasma cytokines underscores the complex timing of inflammatory processes and suggests that obesity-related senescence may be a localized phenomenon not immediately evident in systemic circulation. Moreover, despite the lack of statistically significant differences between conditions observed in the ELISA assays, it is important to note that the absolute concentrations of TNF-α and IL-6 remained relatively low. This suggests that, although there may be subtle variations, the overall pro-inflammatory cytokine levels in these samples do not reach magnitudes typically associated with robust inflammatory responses. To fully understand the effects of obesity on immune aging, longer-term studies or a wider range of markers may be necessary. Taken together, our results support the idea that obesity-driven accumulation of senescent cells and their SASP production enables obese plasma to induce senescence and immunosenescence in recipient tissues, even in the absence of significant changes in physiological or adiposity metrics. This is reinforced by a recent kidney transplant study showing higher levels of senescence markers, p16, p21, and IL-6, and increased SASP factors in young recipients of older organs, whereas older recipients of younger organs experienced improvements in these markers [26]. Similar in vivo findings reported that kidneys from aged donors can expedite systemic senescence in young recipients [27] and that older donor age and the presence of pre-existing cellular senescence in cardiac transplants were correlated with diminished graft survival and functional outcomes [28]. Overall, these findings emphasize that donor-derived senescence, whether caused by obesity or aging, and the related SASP components can directly contribute to aging and immune system dysfunction in recipients. Therefore, future research should prioritize therapies aimed at cellular senescence to counteract immune dysfunction and aging associated with obesity. Studies have indicated that eliminating senescent cells or inhibiting the SASP using serotherapeutic agents could enhance metabolic health. For example, both experimental and clinical evidence have highlighted N-acetylcysteine (NAC) as a promising therapeutic agent. An ex vivo model has demonstrated that NAC reduced key indicators of cellular senescence in the adipose tissue of obese individuals [29]. Moreover, a clinical trial has shown that NAC improved markers of senescence, reduced inflammation, and enhanced insulin sensitivity in obese adults, regardless of weight loss [30]. These results suggest that NAC can serve as an effective therapy targeting cellular senescence for immune and metabolic impairments caused by obesity and highlight the importance of early intervention in obesity to prevent the development of a systemic pro-senescence milieu before the onset of irreversible tissue dysfunction and immunosenescence. Additionally, other senotherapeutic agents (such as dasatinib, quercetin, fisetin, rapamycin, etc.) may offer similar benefits [31], warranting a comprehensive investigation to elucidate their therapeutic potential and comparative efficacy in managing immune and metabolic dysfunctions related to obesity. A key strength of this study lies in its novelty, as it is the first to examine the impact of plasma from obese versus non-obese donors on cellular senescence and inflammation in a recipient animal model, introducing an innovative approach to investigate how obesity influences aging across various tissues. However, some limitations should be acknowledged. The use of C57BL/6 mice may limit the translational relevance of the findings, as results from this strain may not fully represent human physiology. Furthermore, although gene expression analyses offer important insights into intracellular signaling pathways, complementary quantification of protein secretion and assessment of functional outcomes are necessary to better elucidate the relationship between plasma-induced senescence and obesity-related metabolic dysfunction. Importantly, the lack of an immediate effect on weight or epididymal adiposity index following four weeks of exposure to plasma from obese donors suggests that not all obesity-related traits are readily transferable via plasma components, particularly within the specific timeframe and experimental conditions of this study. Conclusions This study introduces a novel model to investigate how obesity influences aging in tissues like adipose tissue and PBMCs by transferring plasma from obese and non-obese donors into recipient mice. The results showed that obese plasma promoted cellular senescence and dysfunction in adipose tissue, even without a significant inflammatory response, and also triggered senescence and inflammatory gene expression in PBMCs, suggesting increased immunosenescence. This indicates that the pro-inflammatory and pro-senescence environment induced by obese plasma is not confined to the original donor, but can actively transmit aging-related alterations and immune impairments to healthy recipient cells and tissues. Despite the molecular changes, systemic cytokine levels remained unchanged, and no significant effects were observed in body weight, adiposity, or thymus index, indicating a localized rather than whole-body impact. These findings highlighted the need for longer or more intense exposure studies, expanded tissue profiling, and identification of specific plasma components driving senescence, such as adipokines, metabolites, and extracellular vesicles. Future work should also explore therapeutic strategies such as senotherapeutics, anti-inflammatory agents, and lifestyle modifications to counteract obesity-related metabolic and immune dysfunction.